UA78492C2 - Use of il-18 inhibitor for treatment and/or prevention of atherosclerosis - Google Patents
Use of il-18 inhibitor for treatment and/or prevention of atherosclerosis Download PDFInfo
- Publication number
- UA78492C2 UA78492C2 UA2002129704A UA2002129704A UA78492C2 UA 78492 C2 UA78492 C2 UA 78492C2 UA 2002129704 A UA2002129704 A UA 2002129704A UA 2002129704 A UA2002129704 A UA 2002129704A UA 78492 C2 UA78492 C2 UA 78492C2
- Authority
- UA
- Ukraine
- Prior art keywords
- inhibitor
- atherosclerosis
- patients
- plaques
- plaque
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract description 107
- 201000001320 Atherosclerosis Diseases 0.000 title abstract description 61
- 238000011282 treatment Methods 0.000 title abstract description 36
- 230000002265 prevention Effects 0.000 title abstract description 27
- 239000003814 drug Substances 0.000 abstract description 20
- 238000004519 manufacturing process Methods 0.000 abstract description 15
- 102000003810 Interleukin-18 Human genes 0.000 abstract description 2
- 108090000171 Interleukin-18 Proteins 0.000 abstract description 2
- 108090000623 proteins and genes Proteins 0.000 description 62
- 102000004169 proteins and genes Human genes 0.000 description 53
- 235000018102 proteins Nutrition 0.000 description 52
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 40
- 230000037396 body weight Effects 0.000 description 38
- 238000000034 method Methods 0.000 description 31
- 102000005962 receptors Human genes 0.000 description 30
- 108020003175 receptors Proteins 0.000 description 30
- 230000000694 effects Effects 0.000 description 27
- 239000005557 antagonist Substances 0.000 description 26
- 230000014509 gene expression Effects 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 25
- 210000001367 artery Anatomy 0.000 description 24
- 239000013612 plasmid Substances 0.000 description 24
- 241000699670 Mus sp. Species 0.000 description 23
- 150000002632 lipids Chemical class 0.000 description 23
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 20
- 230000000302 ischemic effect Effects 0.000 description 19
- 230000003902 lesion Effects 0.000 description 19
- 230000003143 atherosclerotic effect Effects 0.000 description 18
- 230000027455 binding Effects 0.000 description 18
- 229940079593 drug Drugs 0.000 description 17
- 102000001708 Protein Isoforms Human genes 0.000 description 16
- 108010029485 Protein Isoforms Proteins 0.000 description 16
- 235000001014 amino acid Nutrition 0.000 description 16
- 201000010099 disease Diseases 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 239000000203 mixture Substances 0.000 description 16
- 150000001413 amino acids Chemical class 0.000 description 15
- 238000011161 development Methods 0.000 description 15
- 230000000306 recurrent effect Effects 0.000 description 15
- 239000013598 vector Substances 0.000 description 15
- 206010019280 Heart failures Diseases 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 14
- 108060003951 Immunoglobulin Proteins 0.000 description 13
- 208000007536 Thrombosis Diseases 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 13
- 102000018358 immunoglobulin Human genes 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- 208000028867 ischemia Diseases 0.000 description 12
- 210000002540 macrophage Anatomy 0.000 description 12
- 230000003612 virological effect Effects 0.000 description 12
- 102000008186 Collagen Human genes 0.000 description 11
- 108010035532 Collagen Proteins 0.000 description 11
- 229920001436 collagen Polymers 0.000 description 11
- 102000014150 Interferons Human genes 0.000 description 10
- 108010050904 Interferons Proteins 0.000 description 10
- 108020004999 messenger RNA Proteins 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 102000023732 binding proteins Human genes 0.000 description 9
- 108091008324 binding proteins Proteins 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000034994 death Effects 0.000 description 9
- 231100000517 death Toxicity 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 208000025865 Ulcer Diseases 0.000 description 8
- 210000002376 aorta thoracic Anatomy 0.000 description 8
- 235000012000 cholesterol Nutrition 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 239000003925 fat Substances 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 229940079322 interferon Drugs 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 229940126601 medicinal product Drugs 0.000 description 8
- 208000010125 myocardial infarction Diseases 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 206010003210 Arteriosclerosis Diseases 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Natural products N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 230000001154 acute effect Effects 0.000 description 6
- 210000000709 aorta Anatomy 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 210000001715 carotid artery Anatomy 0.000 description 6
- 230000030833 cell death Effects 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 210000003291 sinus of valsalva Anatomy 0.000 description 6
- 210000002460 smooth muscle Anatomy 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 241000283707 Capra Species 0.000 description 5
- 108090000426 Caspase-1 Proteins 0.000 description 5
- 102100035904 Caspase-1 Human genes 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 241001529936 Murinae Species 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 241000181331 Saron Species 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 229960002685 biotin Drugs 0.000 description 5
- 239000011616 biotin Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 238000004393 prognosis Methods 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 231100000397 ulcer Toxicity 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 102000004895 Lipoproteins Human genes 0.000 description 4
- 108090001030 Lipoproteins Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 230000036523 atherogenesis Effects 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 210000004969 inflammatory cell Anatomy 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 230000008054 signal transmission Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 206010002329 Aneurysm Diseases 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 241000283073 Equus caballus Species 0.000 description 3
- 208000035150 Hypercholesterolemia Diseases 0.000 description 3
- 208000034189 Sclerosis Diseases 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 230000035508 accumulation Effects 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 239000003524 antilipemic agent Substances 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000036770 blood supply Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000013171 endarterectomy Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- JLESVLCTIOAHPT-UHFFFAOYSA-N mmai Chemical compound C1=C(C)C(OC)=CC2=C1CC(N)C2 JLESVLCTIOAHPT-UHFFFAOYSA-N 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000002957 persistent organic pollutant Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000000250 revascularization Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000002885 thrombogenetic effect Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 230000036269 ulceration Effects 0.000 description 3
- 230000003313 weakening effect Effects 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 101100163490 Alkalihalobacillus halodurans (strain ATCC BAA-125 / DSM 18197 / FERM 7344 / JCM 9153 / C-125) aroA1 gene Proteins 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 206010007687 Carotid artery stenosis Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920001268 Cholestyramine Polymers 0.000 description 2
- 229920002911 Colestipol Polymers 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010051602 Laziness Diseases 0.000 description 2
- 240000006240 Linum usitatissimum Species 0.000 description 2
- 235000004431 Linum usitatissimum Nutrition 0.000 description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108090000783 Renin Proteins 0.000 description 2
- 102100028255 Renin Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 101150037081 aroA gene Proteins 0.000 description 2
- 101150040872 aroE gene Proteins 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 238000013172 carotid endarterectomy Methods 0.000 description 2
- 208000006170 carotid stenosis Diseases 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000030570 cellular localization Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 2
- 229960002604 colestipol Drugs 0.000 description 2
- 238000005056 compaction Methods 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 229940111134 coxibs Drugs 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 2
- 229960003627 gemfibrozil Drugs 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
- 229960004844 lovastatin Drugs 0.000 description 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 2
- 210000001349 mammary artery Anatomy 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 2
- 229960003912 probucol Drugs 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical group OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- BZBMCJVNCJFKEN-QRPNPIFTSA-N (2s)-2-amino-3-phenylpropanoic acid;1,3-dichloropropan-2-one Chemical compound ClCC(=O)CCl.OC(=O)[C@@H](N)CC1=CC=CC=C1 BZBMCJVNCJFKEN-QRPNPIFTSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 208000025494 Aortic disease Diseases 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 241000587155 Athene Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 241001049165 Caria Species 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- QYQDKDWGWDOFFU-IUODEOHRSA-N Cefotiam Chemical compound CN(C)CCN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CC=3N=C(N)SC=3)[C@H]2SC1 QYQDKDWGWDOFFU-IUODEOHRSA-N 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 206010053172 Fatal outcomes Diseases 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 101000889990 Homo sapiens Apolipoprotein(a) Proteins 0.000 description 1
- 101001094649 Homo sapiens Popeye domain-containing protein 3 Proteins 0.000 description 1
- 101000608234 Homo sapiens Pyrin domain-containing protein 5 Proteins 0.000 description 1
- 101000635799 Homo sapiens Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Proteins 0.000 description 1
- 101000578693 Homo sapiens Target of rapamycin complex subunit LST8 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000001617 Interferon Receptors Human genes 0.000 description 1
- 108010054267 Interferon Receptors Proteins 0.000 description 1
- 241000087801 Ioba Species 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 241000102542 Kara Species 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001214257 Mene Species 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 241000840267 Moma Species 0.000 description 1
- 101001082628 Mus musculus H-2 class II histocompatibility antigen gamma chain Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100039889 Pyrin domain-containing protein 5 Human genes 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 108091007187 Reductases Proteins 0.000 description 1
- 102100030852 Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Human genes 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 239000008049 TAE buffer Substances 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 102000013394 Troponin I Human genes 0.000 description 1
- 108010065729 Troponin I Proteins 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- HGEVZDLYZYVYHD-UHFFFAOYSA-N acetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HGEVZDLYZYVYHD-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 201000008247 brain infarction Diseases 0.000 description 1
- WQAQPCDUOCURKW-UHFFFAOYSA-N butanethiol Chemical compound CCCCS WQAQPCDUOCURKW-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 210000001011 carotid body Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- -1 cholesterol Chemical class 0.000 description 1
- 210000001136 chorion Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 101150116749 chuk gene Proteins 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 102000045903 human LPA Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 108010027775 interleukin-1beta-converting enzyme inhibitor Proteins 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008180 pharmaceutical surfactant Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000004647 pro-inflammatory pathway Effects 0.000 description 1
- 239000003805 procoagulant Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 108091006082 receptor inhibitors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 210000004767 rumen Anatomy 0.000 description 1
- 210000003752 saphenous vein Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000003584 silencer Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000003270 subclavian artery Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000012134 supernatant fraction Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 208000037905 systemic hypertension Diseases 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000563 toxic property Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00109606 | 2000-05-05 | ||
PCT/EP2001/004843 WO2001085201A2 (en) | 2000-05-05 | 2001-04-30 | Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis |
Publications (1)
Publication Number | Publication Date |
---|---|
UA78492C2 true UA78492C2 (en) | 2007-04-10 |
Family
ID=8168631
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA200507913A UA87658C2 (uk) | 2000-05-05 | 2001-04-30 | Застосування il-18 як діагностичного маркера серцевої недостатності |
UA2002129704A UA78492C2 (en) | 2000-05-05 | 2001-04-30 | Use of il-18 inhibitor for treatment and/or prevention of atherosclerosis |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA200507913A UA87658C2 (uk) | 2000-05-05 | 2001-04-30 | Застосування il-18 як діагностичного маркера серцевої недостатності |
Country Status (33)
Country | Link |
---|---|
US (1) | US20040076628A1 (no) |
EP (1) | EP1278540B1 (no) |
JP (1) | JP5122053B2 (no) |
KR (2) | KR100798545B1 (no) |
CN (2) | CN1250286C (no) |
AR (1) | AR035640A1 (no) |
AT (1) | ATE395075T1 (no) |
AU (2) | AU6739001A (no) |
BG (1) | BG65881B1 (no) |
BR (1) | BRPI0110506B8 (no) |
CA (1) | CA2407895C (no) |
CY (1) | CY1110385T1 (no) |
CZ (1) | CZ300792B6 (no) |
DE (1) | DE60134009D1 (no) |
DK (1) | DK1278540T3 (no) |
EA (2) | EA007014B1 (no) |
EE (1) | EE05056B1 (no) |
ES (1) | ES2305082T3 (no) |
HK (2) | HK1055681A1 (no) |
HR (1) | HRP20020828A2 (no) |
HU (1) | HU229375B1 (no) |
IL (2) | IL152567A0 (no) |
ME (1) | ME00554B (no) |
MX (1) | MXPA02010895A (no) |
NO (1) | NO329821B1 (no) |
PL (1) | PL209371B1 (no) |
PT (1) | PT1278540E (no) |
RS (1) | RS50926B (no) |
SI (1) | SI1278540T1 (no) |
SK (1) | SK287761B6 (no) |
UA (2) | UA87658C2 (no) |
WO (1) | WO2001085201A2 (no) |
ZA (1) | ZA200208228B (no) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2399148A1 (en) * | 2000-02-10 | 2001-08-16 | Abbott Laboratories | Antibodies that bind human interleukin-18 and methods of making and using |
CA2435466C (en) * | 2001-01-29 | 2012-04-03 | Applied Research Systems Ars Holding N.V. | Use of il-18 inhibitors for the treatment and/or prevention of heart disease |
CA2445664C (en) * | 2001-05-25 | 2012-03-06 | Ares Trading S.A. | Use of il-18 inhibitors for treating or preventing cns injuries |
US6797727B2 (en) | 2001-07-16 | 2004-09-28 | Transition Therapeutics Inc. | Use of rhein or diacerhein compounds for the treatment or prevention of vascular diseases |
GB0210212D0 (en) * | 2002-05-03 | 2002-06-12 | Univ Southampton | Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability |
US8729124B2 (en) | 2002-03-05 | 2014-05-20 | Pronova Biopharma Norge As | Use of EPA and DHA in secondary prevention |
PT1487541E (pt) * | 2002-03-22 | 2008-12-10 | Inst Nat Sante Rech Med | Utilização de inibidores de il-8 para o tratamento e/ou prevenção de doenças vasculares periféricas |
ATE399872T1 (de) * | 2003-03-11 | 2008-07-15 | Serono Lab | Expressionvektoren, die den promotor des ie2-gens des maus cytomegalovirus enthalten |
EP1622939B1 (en) | 2003-05-13 | 2012-03-14 | Merck Serono SA | Active variants of the il-18 binding protein and medical uses thereof |
US7968684B2 (en) * | 2003-11-12 | 2011-06-28 | Abbott Laboratories | IL-18 binding proteins |
US20080044404A1 (en) * | 2004-04-15 | 2008-02-21 | Anna Cederholm | Annexin V for Preventing Atherothrombosis and Plaque Rupture |
CN101219208B (zh) * | 2005-01-04 | 2010-08-11 | 健能隆医药技术(上海)有限公司 | 白介素-22的医药用途 |
PT1885753E (pt) | 2005-06-03 | 2011-10-06 | Ares Trading Sa | Produção de proteína recombinante de ligação a il-18 |
WO2006131550A1 (en) | 2005-06-10 | 2006-12-14 | Ares Trading S.A. | Process for the purification of il-18 binding protein |
AR082518A1 (es) | 2010-08-25 | 2012-12-12 | Hoffmann La Roche | Anticuerpos contra il-18r1 y usos de los mismos |
JOP20200308A1 (ar) | 2012-09-07 | 2017-06-16 | Novartis Ag | جزيئات إرتباط il-18 |
MD707Z (ro) * | 2013-01-18 | 2014-07-31 | Институт Зоологии Академии Наук Молдовы | Metodă de identificare a secvenţelor polimorfe 4a/4b ale genei sintetazei endoteliale a oxidului nitric |
SG11201601717VA (en) | 2013-09-05 | 2016-04-28 | Ab2 Bio Sa | Il-18 binding protein (il-18bp) in inflammatory diseases |
CN107660150B (zh) | 2015-03-05 | 2023-10-24 | Ab2生物股份有限公司 | Il-18结合蛋白(il-18bp)和抗体在炎性疾病中 |
CN110273591B (zh) | 2019-08-13 | 2023-12-12 | 上海杉脉电子科技发展有限公司 | 一种单动力微型智能锁 |
TW202233675A (zh) | 2020-10-29 | 2022-09-01 | 瑞士商諾華公司 | Il-18拮抗劑用於治療和/或預防異位性皮炎或相關病症之用途 |
CN112972655A (zh) * | 2021-04-16 | 2021-06-18 | 武汉大学 | 白细胞介素12在制备预防、缓解和/或治疗主动脉瘤药物中的应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5985863A (en) * | 1996-09-12 | 1999-11-16 | Vertex Pharmaceuticals, Inc. | Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor |
US5877197A (en) * | 1996-12-16 | 1999-03-02 | Karanewsky; Donald S. | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
IL121860A0 (en) * | 1997-08-14 | 1998-02-22 | Yeda Res & Dev | Interleukin-18 binding proteins their preparation and use |
CA2276216A1 (en) * | 1998-06-24 | 1999-12-24 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | An artificial peptide capable of neutralizing the biological activity of interleukin-18 |
EP0987552A3 (en) * | 1998-08-31 | 2000-06-07 | Pfizer Products Inc. | Diarylsulfonylurea binding proteins |
WO2000012555A1 (fr) * | 1998-09-01 | 2000-03-09 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Proteine de liaison de l'interleukine 18 |
-
2001
- 2001-04-30 UA UAA200507913A patent/UA87658C2/uk unknown
- 2001-04-30 EA EA200401183A patent/EA007014B1/ru not_active IP Right Cessation
- 2001-04-30 DE DE60134009T patent/DE60134009D1/de not_active Expired - Lifetime
- 2001-04-30 PL PL365697A patent/PL209371B1/pl unknown
- 2001-04-30 AU AU6739001A patent/AU6739001A/xx active Pending
- 2001-04-30 DK DK01945064T patent/DK1278540T3/da active
- 2001-04-30 MX MXPA02010895A patent/MXPA02010895A/es active IP Right Grant
- 2001-04-30 CN CNB018090540A patent/CN1250286C/zh not_active Expired - Lifetime
- 2001-04-30 HU HU0301991A patent/HU229375B1/hu unknown
- 2001-04-30 EE EEP200200620A patent/EE05056B1/xx unknown
- 2001-04-30 ES ES01945064T patent/ES2305082T3/es not_active Expired - Lifetime
- 2001-04-30 AU AU2001267390A patent/AU2001267390B2/en not_active Expired
- 2001-04-30 JP JP2001581854A patent/JP5122053B2/ja not_active Expired - Lifetime
- 2001-04-30 KR KR1020077014038A patent/KR100798545B1/ko active IP Right Grant
- 2001-04-30 US US10/275,341 patent/US20040076628A1/en not_active Abandoned
- 2001-04-30 SK SK1556-2002A patent/SK287761B6/sk not_active IP Right Cessation
- 2001-04-30 IL IL15256701A patent/IL152567A0/xx unknown
- 2001-04-30 CN CN2006100092901A patent/CN1841066B/zh not_active Expired - Lifetime
- 2001-04-30 PT PT01945064T patent/PT1278540E/pt unknown
- 2001-04-30 CZ CZ20023644A patent/CZ300792B6/cs not_active IP Right Cessation
- 2001-04-30 WO PCT/EP2001/004843 patent/WO2001085201A2/en active IP Right Grant
- 2001-04-30 AT AT01945064T patent/ATE395075T1/de active
- 2001-04-30 SI SI200130832T patent/SI1278540T1/sl unknown
- 2001-04-30 KR KR1020027014755A patent/KR20030016254A/ko not_active Application Discontinuation
- 2001-04-30 BR BRPI0110506A patent/BRPI0110506B8/pt not_active IP Right Cessation
- 2001-04-30 ME MEP-2008-640A patent/ME00554B/me unknown
- 2001-04-30 RS YUP-826/02A patent/RS50926B/sr unknown
- 2001-04-30 CA CA2407895A patent/CA2407895C/en not_active Expired - Lifetime
- 2001-04-30 EP EP01945064A patent/EP1278540B1/en not_active Expired - Lifetime
- 2001-04-30 UA UA2002129704A patent/UA78492C2/uk unknown
- 2001-04-30 EA EA200201175A patent/EA005410B1/ru not_active IP Right Cessation
- 2001-05-04 AR ARP010102129A patent/AR035640A1/es unknown
-
2002
- 2002-10-11 ZA ZA2002/08228A patent/ZA200208228B/en unknown
- 2002-10-16 HR HRP20020828 patent/HRP20020828A2/hr not_active Application Discontinuation
- 2002-10-24 BG BG107218A patent/BG65881B1/bg unknown
- 2002-10-31 IL IL152567A patent/IL152567A/en active IP Right Grant
- 2002-11-05 NO NO20025307A patent/NO329821B1/no not_active IP Right Cessation
-
2003
- 2003-11-05 HK HK03107981A patent/HK1055681A1/xx not_active IP Right Cessation
-
2007
- 2007-03-02 HK HK07102380.7A patent/HK1094909A1/xx not_active IP Right Cessation
-
2008
- 2008-06-30 CY CY20081100684T patent/CY1110385T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA78492C2 (en) | Use of il-18 inhibitor for treatment and/or prevention of atherosclerosis | |
US7786274B2 (en) | Anti-IL-20 antibody and its use in treating IL-20 associated inflammatory diseases | |
UA85531C2 (uk) | Застосування il-18 інгібіторів для лікування або попередження пов'язаної з сепсисом дисфункції серця | |
UA81114C2 (en) | Novel antibodies to tissue factor as anticoagulants | |
JPH11507332A (ja) | 結合組織成長因子 | |
PT975672E (pt) | Anticorpos para inibir a coagulação sanguínea e métodos para a sua utilização | |
US20220072032A1 (en) | Inhibitors of pcsk9 for treatment of lipoprotein metabolism disorders | |
JP2004527242A (ja) | ヒスチジンリッチ糖タンパク質 | |
BG65579B1 (bg) | Състав за лечение на възпалително нарушение | |
EA010180B1 (ru) | Применение ингибитора il-18 для приготовления лекарственного средства для лечения и/или профилактики кардиомиопатии | |
US20050175609A1 (en) | Placental growth factor as a target for the treatment of osteoporosis | |
KR101975778B1 (ko) | Ptp4a1 단백질 또는 이를 암호화 하는 폴리뉴클레오티드를 유효성분으로 함유하는 혈관염증질환 예방 또는 치료용 조성물 | |
AU2005211606B2 (en) | Use of IL-18 inhibitors for the treatment and/or prevention of atherosclerosis |